The PRESENILIN genes (PSEN1, PSEN2) encoding for their respective proteins have critical roles in many aspects of Alzheimer’s disease (AD) pathogenesis. The PS2V transcript of PSEN2 encodes a truncated protein and is upregulated in AD brains; however, its relevance to AD and disease progression remains to be determined.
Objective:
Assess transcript levels in postmortem AD and non-AD brain tissue and in lymphocytes collected under the Australian Imaging Biomarker and Lifestyle (AIBL) study.
Methods:
Full length PSEN2 and PS2V transcript levels were assessed by quantitative digital PCR in postmortem brain tissue (frontal cortex and hippocampus) from control, AD, frontotemporal dementia (FTD), and Lewy body dementia (LBD). Transcript levels were also assessed in lymphocytes obtained from the Perth subset of the AIBL study (n = 160). Linear regression analysis was used to assess correlations between transcript copy number and brain volume and neocortical amyloid load.
Results:
PS2V levels increased in AD postmortem brain but PS2V was also present at significant levels in FTD and LBD brains. PS2V transcript was detected in lymphocytes and PS2V/PSEN2 ratios were increased in mild cognitive impairment (p = 0.024) and AD (p = 0.019) groups compared to control group. Increased ratios were significantly correlated with hippocampal volumes only (n = 62, β= –0.269, p = 0.03).
Conclusion:
Taken together, these results suggest that PS2V may be a marker of overall neurodegeneration.
JayneT, NewmanM, VerdileG, SutherlandG, MunchG, MusgraveI, Moussavi NikSH, LardelliM (2016) Evidence for and against a pathogenic role of reduced gamma-secretase activity in familial Alzheimer’s disease. J Alzheimers Dis52, 781–799.
2.
VillemagneVL, BurnhamS, BourgeatP, BrownB, EllisKA, SalvadoO, SzoekeC, MacaulaySL, MartinsR, MaruffP, AmesD, RoweCC, MastersCL, Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group (2013) Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: A prospective cohort study. Lancet Neurol12, 357–367.
AmtulZ, LewisPA, PiperS, CrookR, BakerM, FindlayK, SingletonA, HoggM, YounkinL, YounkinSG, HardyJ, HuttonM, BoeveBF, Tang-WaiD, GoldeTE (2002) A presenilin 1 mutation associated with familial frontotemporal dementia inhibits gamma-secretase cleavage of APP and notch. Neurobiol Dis9, 269–273.
6.
DermautB, Kumar-SinghS, EngelborghsS, TheunsJ, RademakersR, SaerensJ, PickutBA, PeetersK, van den BroeckM, VennekensK, ClaesS, CrutsM, CrasP, MartinJJ, Van BroeckhovenC, De DeynPP (2004) A novel presenilin 1 mutation associated with Pick’s disease but not beta-amyloid plaques. Ann Neurol55, 617–626.
HiltunenM, HelisalmiS, MannermaaA, AlafuzoffI, KoivistoAM, LehtovirtaM, PirskanenM, SulkavaR, VerkkoniemiA, SoininenH (2000) Identification of a novel 4.6-kb genomic deletion in presenilin-1 gene which results in exclusion of exon 9 in a Finnish early onset Alzheimer’s disease family: An Alu core sequence-stimulated recombination?Eur J Hum Genet8, 259–266.
12.
Perez-TurJ, FroelichS, PriharG, CrookR, BakerM, DuffK, WraggM, BusfieldF, LendonC, ClarkRF, et al. (1995) A mutation in Alzheimer’s disease destroying a splice acceptor site in the presenilin-1 gene. Neuroreport7, 297–301.
13.
RogaevEI, SherringtonR, WuC, LevesqueG, LiangY, RogaevaEA, IkedaM, HolmanK, LinC, LukiwWJ, de JongPJ, FraserPE, RommensJM, St George-HyslopP (1997) Analysis of the 5’ sequence, genomic structure, and alternative splicing of the presenilin-1 gene (PSEN1) associated with early onset Alzheimer disease. Genomics40, 415–424.
14.
KwokJB, HallidayGM, BrooksWS, DoliosG, LaudonH, MurayamaO, HalluppM, BadenhopRF, VickersJ, WangR, NaslundJ, TakashimaA, GandySE, SchofieldPR (2003) Presenilin-1 mutation L271V results in altered exon 8 splicing and Alzheimer’s disease with non-cored plaques and no neuritic dystrophy. J Biol Chem278, 6748–6754.
15.
PriharG, FuldnerRA, Perez-TurJ, LincolnS, DuffK, CrookR, HardyJ, PhilipsCA, VenterC, TalbotC, ClarkRF, GoateA, LiJ, PotterH, KarranE, RobertsGW, HuttonM, AdamsMD (1996) Structure and alternative splicing of the presenilin-2 gene. Neuroreport7, 1680–1684.
16.
TakahashiN, KariyaS, HiranoM, UenoS (2003) Two novel spliced presenilin 2 transcripts in human lymphocyte with oxidant stress and brain. Mol Cell Biochem252, 279–283.
17.
SmithMJ, SharplesRA, EvinG, McLeanCA, DeanB, PaveyG, FantinoE, CottonRG, ImaizumiK, MastersCL, CappaiR, CulvenorJG (2004) Expression of truncated presenilin 2 splice variant in Alzheimer’s disease, bipolar disorder, and schizophrenia brain cortex. Brain Res Mol Brain Res127, 128–135.
18.
SatoN, ImaizumiK, ManabeT, TaniguchiM, HitomiJ, KatayamaT, YonedaT, MoriharaT, YasudaY, TakagiT, KudoT, TsudaT, ItoyamaY, MakifuchiT, FraserPE, St George-HyslopP, TohyamaM (2001) Increased production of beta-amyloid and vulnerability to endoplasmic reticulum stress by an aberrant spliced form of presenilin 2. J Biol Chem276, 2108–2114.
19.
BragginJE, BucksSA, CourseMM, SmithCL, SopherB, OsnisL, ShueyKD, Domoto-ReillyK, CasoC, KinoshitaC, ScherpelzKP, CrossC, GrabowskiT, NikSHM, NewmanM, GardenGA, LeverenzJB, TsuangD, LatimerC, Gonzalez-CuyarLF, KeeneCD, MorrisonRS, RhoadsK, WijsmanEM, DorschnerMO, LardelliM, YoungJE, ValdmanisPN, BirdTD, JayadevS (2019) Alternative splicing in a presenilin 2 variant associated with Alzheimer disease. Ann Clin Transl Neurol6, 762–777.
SharmanMJ, Moussavi NikSH, ChenMM, OngD, WijayaL, LawsSM, TaddeiK, NewmanM, LardelliM, MartinsRN, VerdileG (2013) The guinea pig as a model for sporadic Alzheimer’s disease (AD): The impact of cholesterol intake on expression of AD-related genes. PLoS One8, e66235.
22.
JayadevS, LeverenzJB, SteinbartE, StahlJ, KlunkW, YuCE, BirdTD (2010) Alzheimer’s disease phenotypes and genotypes associated with mutations in presenilin 2. Brain133, 1143–1154.
23.
Moussavi NikSH, NewmanM, WilsonL, EbrahimieE, WellsS, MusgraveI, VerdileG, MartinsRN, LardelliM (2015) Alzheimer’s disease-related peptide PS2V plays ancient, conserved roles in suppression of the unfolded protein response under hypoxia and stimulation of gamma-secretase activity. Hum Mol Genet24, 3662–3678.
24.
SatoN, HoriO, YamaguchiA, LambertJC, Chartier-HarlinMC, RobinsonPA, DelacourteA, SchmidtAM, FuruyamaT, ImaizumiK, TohyamaM, TakagiT (1999) A novel presenilin-2 splice variant in human Alzheimer’s disease brain tissue. J Neurochem72, 2498–2505.
25.
EllisKA, BushAI, DarbyD, De FazioD, FosterJ, HudsonP, LautenschlagerNT, LenzoN, MartinsRN, MaruffP, MastersC, MilnerA, PikeK, RoweC, SavageG, SzoekeC, TaddeiK, VillemagneV, WoodwardM, AmesD, AIBL Research Group (2009) The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer’s disease. Int Psychogeriatr21, 672–687.
26.
BakerM (2012) Digital PCR hits its stride. Nat Methods9, 541–544.
27.
Fazekas de StG (1982) The evaluation of limiting dilution assays. J Immunol Methods49, R11–23.
28.
HuggettJF, WhaleA (2013) Digital PCR as a novel technology and its potential implications for molecular diagnostics. Clin Chem59, 1691–1693.
29.
PorterT, BurnhamSC, MilicicL, SavageG, MaruffP, LimYY, LiQX, AmesD, MastersCL, Rainey-SmithS, RoweCC, SalvadoO, GrothD, VerdileG, VillemagneVL, LawsSM, AIBL Research Group (2018) Utility of an Alzheimer’s disease risk-weighted polygenic risk score for predicting rates of cognitive decline in preclinical Alzheimer’s disease: A prospective longitudinal study. J Alzheimers Dis66, 1193–1211.
30.
RoweCC, EllisKA, RimajovaM, BourgeatP, PikeKE, JonesG, FrippJ, Tochon-DanguyH, MorandeauL, O’KeefeG, PriceR, RanigaP, RobinsP, AcostaO, LenzoN, SzoekeC, SalvadoO, HeadR, MartinsR, MastersCL, AmesD, VillemagneVL (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging31, 1275–1283.
31.
ClarkCM, SchneiderJA, BedellBJ, BeachTG, BilkerWB, MintunMA, PontecorvoMJ, HeftiF, CarpenterAP, FlitterML, KrautkramerMJ, KungHF, ColemanRE, DoraiswamyPM, FleisherAS, SabbaghMN, SadowskyCH, ReimanEP, ZehntnerSP, SkovronskyDM, AV45-A07 Study Group (2011) Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA305, 275–283.
32.
VandenbergheR, Van LaereK, IvanoiuA, SalmonE, BastinC, TriauE, HasselbalchS, LawI, AndersenA, KornerA, MinthonL, GarrauxG, NelissenN, BormansG, BuckleyC, OweniusR, ThurfjellL, FarrarG, BrooksDJ (2010) 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol68, 319–329.
33.
BourgeatP, VillemagneVL, DoreV, BrownB, MacaulaySL, MartinsR, MastersCL, AmesD, EllisK, RoweCC, SalvadoO, FrippJ, AIBL Research Group (2015) Comparison of MR-less PiB SUVR quantification methods. Neurobiol Aging36(Suppl 1), S159–166.
34.
DoreV, VillemagneVL, BourgeatP, FrippJ, AcostaO, ChetelatG, ZhouL, MartinsR, EllisKA, MastersCL, AmesD, SalvadoO, RoweCC (2013) Cross-sectional and longitudinal analysis of the relationship between Abeta deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. JAMA Neurol70, 903–911.
35.
SatohJ, KurodaY (1999) Constitutive and cytokine-regulated expression of presenilin-1 and presenilin-2 genes in human neural cell lines. Neuropathol Appl Neurobiol25, 492–503.
36.
LukiwWJ, GordonWC, RogaevEI, ThompsonH, BazanNG (2001) Presenilin-2 (PS2) expression up-regulation in a model of retinopathy of prematurity and pathoangiogenesis. Neuroreport12, 53–57.
37.
MohuczyD, QianK, PhillipsMI (2002) Presenilins in the heart: Presenilin-2 expression is increased by low glucose and by hypoxia in cardiac cells. Regul Pept110, 1–7.
